Growth Metrics

Eli Lilly (LLY) Long-Term Deferred Tax (2017 - 2025)

Historic Long-Term Deferred Tax for Eli Lilly (LLY) over the last 9 years, with Q4 2025 value amounting to $10.0 billion.

  • Eli Lilly's Long-Term Deferred Tax rose 2447.19% to $10.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $10.0 billion, marking a year-over-year increase of 2447.19%. This contributed to the annual value of $10.0 billion for FY2025, which is 2447.19% up from last year.
  • According to the latest figures from Q4 2025, Eli Lilly's Long-Term Deferred Tax is $10.0 billion, which was up 2447.19% from $9.0 billion recorded in Q3 2025.
  • Eli Lilly's 5-year Long-Term Deferred Tax high stood at $10.0 billion for Q4 2025, and its period low was $2.4 billion during Q2 2022.
  • Its 5-year average for Long-Term Deferred Tax is $5.1 billion, with a median of $4.2 billion in 2023.
  • Its Long-Term Deferred Tax has fluctuated over the past 5 years, first crashed by 1205.13% in 2021, then skyrocketed by 9611.51% in 2023.
  • Eli Lilly's Long-Term Deferred Tax (Quarter) stood at $2.5 billion in 2021, then grew by 12.2% to $2.8 billion in 2022, then soared by 96.12% to $5.5 billion in 2023, then soared by 46.08% to $8.0 billion in 2024, then increased by 24.47% to $10.0 billion in 2025.
  • Its Long-Term Deferred Tax stands at $10.0 billion for Q4 2025, versus $9.0 billion for Q3 2025 and $9.4 billion for Q2 2025.